Pricing Sign in

BHC

Bausch & Lomb Incorporateddistress 0/10 · well-funded / low risk

$4.53-1%today-46% from 52w high

bauschhealth.com20,300 employeesLaval, QCDrug Manufacturers - Specialty & Generic

Lead: Hepatitis · est. market ~$10B (approx, global)

Revenue

$2524M

Liquidity

$1299M

Runway

—

Shares 1y

+1%

Price & events

-31.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.8%

1D

-8.2%

1W

-5.7%

1M

-18.3%

3M

-23.4%

6M

-32.0%

1Y

-40.2%

2Y

-84.2%

5Y

-78.8%

All

Overview

Market Cap: $1.69B
Enterprise Value: $20.27B
Volume: 72.80K
52 Week Range: $4.52 – $8.34
Total Shares: 373.48M
Float Shares: 259.89M
Short %: 2.46%
% Held by Insiders: 11.14%
% Held by Institutions: 65.06%
RVOL: 0.03x
Beta: 0.42

Pipeline stages · 3 programs

Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-11

Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-02

Larsucosterol

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-11

Pipeline · 3 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-11 Estimated 50% readout ~2026-12-16	Phase 2	Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane	Dry Eye Disease	—	recruiting
2027-02 Estimated 50% readout ~2027-03-18	Phase 2	Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic	Pain, Postoperative	—	not yet recruiting
2027-11 Estimated 50% readout ~2028-01-15	Phase 3	Larsucosterolbreakthrough	Hepatitis	—	recruiting

Catalyst news & presentations · 6

2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
early 2026readoutPhase 3rifaximin SSD · Efficacy and safety results from two Phase 3 studies (RED-C program) expected.SEC 8-K
January 23, 2026readoutPhase 3amorphous-rifaximin SSD · Topline results of two global Phase 3 RED-C trials announced.SEC 8-K
January 14, 2026conferencedata presentationsecondary44th Annual J.P. Morgan Healthcare Conference presentation.SEC 8-K
2025-09-11partnershipBausch Health acquires DURECT, becoming sole owner after tender offer and merger.SEC 8-K
2025-07-29partnershiplarsucosterol · Bausch Health to acquire DURECT, including larsucosterol, via merger agreement.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 373,475,644 · 0 offerings/1y · 0 PIPEs

2026-01-028-Kmaterial_agreement
2025-12-298-Kmaterial_agreement
2025-06-278-Kmaterial_agreement
2025-05-218-Kmaterial_agreement
2025-04-158-Kmaterial_agreement
2025-04-098-Kmaterial_agreement
2024-11-018-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

hold · target $7 (+64% upside) · 5 analysts

2026-04-27RBC CapitalSector Perform
2026-02-25BarclaysEqual-Weight
2026-01-07Truist SecuritiesHold
2025-12-09BarclaysEqual-Weight
2025-05-02RBC CapitalSector Perform
2025-02-06JefferiesBuy → Hold

Competitors — Hepatitis

GSKGSK plc$217.0B · D1
GILDGILEAD SCIENCES, INC.$159.5B · D2
REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
MIRMMirum Pharmaceuticals, Inc.$6.8B · D2
VIRVir Biotechnology, Inc.$1.6B · D4
GYREGYRE THERAPEUTICS, INC.$571M · D1
ASMBASSEMBLY BIOSCIENCES, INC.$402M · D8
ALGSAligos Therapeutics, Inc.$217M · D3
DTILPRECISION BIOSCIENCES INC$185M · D6
BRNSBarinthus Biotherapeutics plc.$25M · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.